Brief: 3D Signatures receives first prostate cancer blood samples for clinical trial
27/04/2017 12:00
April 27 (Reuters) - 3D Signatures Inc DXD.V :
* 3D Signatures receives first prostate cancer blood samples
for precise clinical trial
Source text for Eikon: ID:nGNXNSTNFa
Further company coverage: DXD.V
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Telo Genomics
See all newsBrief: Telo Genomics Announces Positive Results Of Smoldering Multiple Myeloma Proof Of Concept Study
Brief: Telo Genomics Announces Final Assignment Of Patents On Hematological Cancers, Liquid Biopsy & Alzheimer's Disease
Brief: Telo Genomics Announces Multiple Myeloma Collaboration With Mayo Clinic
Brief: 3D Signatures Announces Name Change To Telo Genomics Corp
Brief: 3D Signatures Says Current Board And Executive Management Team Do Not Intend To File For Bankruptcy